Industries
Hospitals, biotechnology, clinical research organizations, medical laboratories, genomics companies, medical imaging centers, and medical device and pharmaceutical manufacturers all move through regulatory affairs and clinical evaluation before a purchase ever reaches procurement - not a generic health-vendor pitch.
Our Approach
Life sciences buyers are research and clinically led, and regulatory fit is non-negotiable before anything else gets evaluated. We lead with scientific or clinical credibility relevant to the buyer's specific function - trial execution for CROs, turnaround time for diagnostics and imaging, regulatory fit for device and pharma manufacturers - rather than a generic life-sciences pitch.
Buyer Personas
VP / Director of Clinical Operations
Workflow owner
Cares whether a new vendor disrupts existing clinical or research workflow.
Regulatory Affairs Lead
Compliance gatekeeper
Clears vendors on regulatory fit before purchasing can move forward.
VP R&D / Research Director
Scientific evaluator
Evaluates vendors on scientific credibility and data accuracy.
Lab / Imaging Operations Manager
Turnaround-time owner
Feels equipment reliability and turnaround time pressure directly.
What To Expect
Reply-rate and timeline ranges are the same figures published on our Cold Email Outreach page, applied to this vertical - not a new claim specific to it.
Sample Opening Email
Subject: regulatory and workflow fit for [Function]
Hi {{FirstName}}, Most teams in [function] we work with want to know one thing before anything else: does this add steps to an already regulated process, or genuinely remove them. Worth 15 minutes to walk through the regulatory and workflow fit specifically? [Sender name]
Leads with regulatory/workflow fit, not clinical claims - avoids compliance-risky language across this whole cluster
FAQ
Hospitals & Urgent Care, Biotechnology & Genetic Engineering, Clinical Research Organizations (CRO), Medical Laboratories & Diagnostics, Medical Genomics & DNA Sequencing, Medical Imaging Centers, Medical Device Manufacturing, and Pharmaceutical Manufacturing.
We never reference patient data or make clinical efficacy claims in cold outreach - messaging stays focused on operational, workflow, and regulatory-fit impact regardless of sub-sector.
Regulatory and clinical review adds real steps most industries don't have, and buying committees typically run several stakeholders deep - we plan follow-up cadences accordingly.
Pay only for meetings you confirm were a good fit.
Book a Call